RECURSION PHARMACEUT

RXRX
Delayed Quote. Delayed  - 05/18 04:00:00 pm
5.62USD -8.02%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company decoding biology by integrating technology across biology, chemistry, automation, machine learning, and engineering to industrialize drug discovery. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.
Sales per Business
20202021
Biotechnology3.96100%10.18100%
USD in Million
Sales per region
20202021
United States3.96100%10.18100%
USD in Million
Managers
Name Title
Chistopher C. Gibson Chief Executive Officer & Director
Tina Larson Chief Operating Officer
Michael Secora Chief Financial Officer
Ramon Martin Chavez Márquez Independent Chairman
Benjamin Mabey Vice President-Software Engineering
Ramona Doyle Chief Medical Officer
Jordan Christensen Vice President-Engineering
Ganesh Kumar Jagannathan Chief Information Security Officer & VP-IT
Blake Borgeson Independent Director
Dean Y. Li Independent Director
Shareholders
Name Equities %
Baillie Gifford & Co. 21,981,604 13.6%
Mubadala Investment Co. (Private Equity) 15,803,786 9.77%
DCVC Management Co. LLC 13,619,224 8.42%
Lux Capital Group LLC 13,021,519 8.05%
Blake Borgeson 7,652,446 4.73%
Bayer Aktiengesellschaft 7,453,926 4.61%
Steven Theodere Stull 7,422,358 4.59%
Obvious Management Services LLC 5,977,631 3.70%
The Vanguard Group, Inc. 5,936,121 3.67%
SSgA Funds Management, Inc. 4,656,727 2.88%
Company contact information
Recursion Pharmaceuticals, Inc.
41 South Rio Grande Street
Salt Lake City, UT 84101

Phone : +1.385.269.0203
Fax : +1.801.821.2872
Web : http://www.recursion.com
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
RECURSION PHARMACEUTICALS, INC.-64.33%1 051
GILEAD SCIENCES, INC.-12.99%79 248
REGENERON PHARMACEUTICALS, INC.5.71%71 927
VERTEX PHARMACEUTICALS19.24%66 967
WUXI APPTEC CO., LTD.-18.77%42 682
BIONTECH SE-38.01%38 834
GENMAB A/S-20.15%19 472
ARGENX SE-4.76%17 281
BEIGENE, LTD.-48.85%14 298
NEUROCRINE BIOSCIENCES, INC.0.74%8 200
EXELIXIS, INC.13.18%6 636
LEGEND BIOTECH CORPORATION-10.13%6 461
SAREPTA THERAPEUTICS, INC.-20.82%6 239
HALOZYME THERAPEUTICS, INC.3.68%6 125
INTRA-CELLULAR THERAPIES, INC.13.51%5 604
BIOCON LIMITED-9.38%5 074
ASCENDIS PHARMA A/S-33.87%4 965
MARAVAI LIFESCIENCES HOLDINGS, INC.-22.84%4 253
CEREVEL THERAPEUTICS HOLDINGS, INC.-19.90%3 851
ULTRAGENYX PHARMACEUTICAL INC.-35.37%3 801
ARROWHEAD PHARMACEUTICALS, INC.-46.05%3 782
Brand Portfolio
» More brands of Recursion Pharmaceuticals, Inc.